EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC) cases [1,2] and is correlated with a higher rate of recurrence, metastasis, and lower survival [3,4,5]. Here, EGFR is linked to triple-negative breast carcinoma.